2021
Associations of Microvascular Complications With the Risk of Cardiovascular Disease in Type 1 Diabetes.
Gubitosi-Klug R, Gao X, Pop-Busui R, de Boer IH, White N, Aiello LP, Miller R, Palmer J, Tamborlane W, Wallia A, Kosiborod M, Lachin JM, Bebu I. Associations of Microvascular Complications With the Risk of Cardiovascular Disease in Type 1 Diabetes. Diabetes Care 2021, 44: 1499-1505. PMID: 33980605, PMCID: PMC8323173, DOI: 10.2337/dc20-3104.Peer-Reviewed Original ResearchConceptsMajor adverse cardiovascular eventsAlbumin excretion rateNonfatal myocardial infarctionSubsequent cardiovascular diseaseCardiovascular diseaseMicrovascular complicationsMyocardial infarctionMicrovascular diseaseSubsequent riskDCCT/EDIC cohortTraditional CVD risk factorsUrinary albumin excretion rateAdvanced microvascular diseaseSubclinical myocardial infarctionAdverse cardiovascular eventsCoronary artery revascularizationCVD risk factorsGlomerular filtration rateSignificant macular edemaType 1 diabetesProportional hazards modelRetinal fundus photographyArtery revascularizationComplications StudyNonfatal stroke
2010
The Cost-Effectiveness of Continuous Glucose Monitoring in Type 1 Diabetes
Huang ES, O'Grady M, Basu A, Winn A, John P, Lee J, Meltzer D, Kollman C, Laffel L, Tamborlane W, Weinzimer S, Wysocki T, . The Cost-Effectiveness of Continuous Glucose Monitoring in Type 1 Diabetes. Diabetes Care 2010, 33: 1269-1274. PMID: 20332354, PMCID: PMC2875436, DOI: 10.2337/dc09-2042.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioContinuous glucose monitoringType 1 diabetic patientsImproved glucose controlCost-effectiveness analysisGlucose controlDiabetic patientsGlucose monitoringBenefits of CGMType 1 diabetes complicationsTest strip useType 1 diabetesCost-effectiveness ratioStandard glucose monitoringMicrovascular complicationsDiabetes complicationsTrial populationSocietal cost-effectiveness analysisGlycemic benefitsLong-term effectsMAIN OUTCOMELife benefitsQALY thresholdStrip useTrial data
2005
Insulin Pump Treatment of Childhood Type 1 Diabetes
Weinzimer SA, Sikes KA, Steffen AT, Tamborlane WV. Insulin Pump Treatment of Childhood Type 1 Diabetes. Pediatric Clinics Of North America 2005, 52: 1677-1688. PMID: 16301088, DOI: 10.1016/j.pcl.2005.07.004.Peer-Reviewed Original ResearchConceptsContinuous subcutaneous insulin infusionQuality of lifeLong-term microvascular complicationsEfficacy of CSIINormal blood sugar levelsType 1 diabetes mellitusInsulin pump treatmentChildhood Type 1Risk of hypoglycemiaBlood sugar levelsSubcutaneous insulin infusionNew insulin analoguesTreatment of childrenMicrovascular complicationsDiabetes mellitusPump treatmentSevere hypoglycemiaHemoglobin levelsTreatment optionsInsulin infusionClinical studiesAge of childrenInsulin analoguesType 1Weight gain
2004
Rediscovery of insulin pump treatment of childhood type 1 diabetes.
Weinzimer SA, Doyle EA, Steffen AT, Sikes KA, Tamborlane WV. Rediscovery of insulin pump treatment of childhood type 1 diabetes. Minerva Medica 2004, 95: 85-92. PMID: 15272243.Peer-Reviewed Original ResearchConceptsContinuous subcutaneous insulin infusionInsulin pump therapyQuality of lifeSevere hypoglycemiaPump therapyLong-term microvascular complicationsEfficacy of CSIIType 1 diabetes mellitusWeight gainChildhood type 1 diabetesExcessive weight gainBasal infusion rateSubcutaneous insulin infusionType 1 diabetesNew insulin analoguesTreatment of childrenContinuous glucose monitoringMicrovascular complicationsDiabetes mellitusPediatric patientsHemoglobin levelsNocturnal hypoglycemiaTreatment optionsNormal glycemiaInsulin infusion
1982
Long-term improvement of metabolic control with the insulin pump does not reverse diabetic microangiopathy.
Tamborlane WV, Puklin JE, Bergman M, Verdonk C, Rudolf MC, Felig P, Genel M, Sherwin R. Long-term improvement of metabolic control with the insulin pump does not reverse diabetic microangiopathy. Diabetes Care 1982, 5 Suppl 1: 58-64. PMID: 7188047.Peer-Reviewed Original ResearchConceptsPump treatmentProliferative retinopathyMetabolic controlInsulin pumpType I diabetic patientsFirst monthInsulin pump treatmentRetinal fluorescein leakageDiabetic microvascular complicationsTotal daily doseNormal glucose metabolismLong-term improvementBackground retinopathyMicrovascular complicationsCreatinine clearanceDiabetic nephropathyRenal functionSerum creatinineDaily doseDiabetic patientsDiabetic microangiopathyHemoglobin levelsPump therapyPlasma glucoseClinical endpoints